Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: A retrospective follow-up study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
02
2021
accepted:
14
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Drug resistance tuberculosis (DR-TB) patients' mortality and loss to follow-up (LTF) from treatment and care is a growing worry in Ethiopia. However, little is known about predictors of mortality and LTF among drug-resistant tuberculosis patients in Oromia region, Ethiopia. The current study aimed to identify predictors of mortality and loss to follow-up among drug resistance tuberculosis patients in Oromia Hospitals, Ethiopia. A retrospective follow up study was carried out from 01 November 2012 to 31 December 2017 among DR-TB patients after calculating sample size using single proportion population formula. Mean, median, Frequency tables and bar charts were used to describe patients' characteristics in the cohort. The Kaplan-Meier curve was used to estimate the probability of death and LTF after the treatment was initiated. The log-rank test was used to compare time to death and time to LTF. The Cox proportional hazard model was used to determine predictors of mortality and LTF after DR-TB diagnosis. The Crude and adjusted Cox proportional hazard ratio was used to measure the strength of association whereas p-value less than 0.05 were used to declare statistically significant predictors. A total of 406 DR-TB patients were followed for 7084 person-months observations. Among the patients, 71 (17.5%) died and 32 (7.9%) were lost to follow up (LTF). The incidence density of death and LTF in the cohort was 9.8 and 4.5 per 1000 person-months, respectively. The median age of the study participants was 28 years (IQR: 27.1, 29.1). The overall cumulative survival probability of patients at the end of 24 months was 77.5% and 84.5% for the mortality and LTF, respectively. The independent predictors of death was chest radiographic findings (AHR = 0.37, 95% CI: 0.17-0.79) and HIV serostatus 2.98 (95% CI: 1.72-5.19). Drug adverse effect (AHR = 6.1; 95% CI: 2.5, 14.34) and culture test result (AHR = 0.1; 95% CI: 0.1, 0.3) were independent predictors of LTF. This study concluded that drug-resistant tuberculosis mortality and LTF remains high in the study area. Continual support of the integration of TB/HIV service with emphasis and work to identified predictors may help in reducing drug-resistant tuberculosis mortality and LTF.
Sections du résumé
BACKGROUND
Drug resistance tuberculosis (DR-TB) patients' mortality and loss to follow-up (LTF) from treatment and care is a growing worry in Ethiopia. However, little is known about predictors of mortality and LTF among drug-resistant tuberculosis patients in Oromia region, Ethiopia. The current study aimed to identify predictors of mortality and loss to follow-up among drug resistance tuberculosis patients in Oromia Hospitals, Ethiopia.
METHODS
A retrospective follow up study was carried out from 01 November 2012 to 31 December 2017 among DR-TB patients after calculating sample size using single proportion population formula. Mean, median, Frequency tables and bar charts were used to describe patients' characteristics in the cohort. The Kaplan-Meier curve was used to estimate the probability of death and LTF after the treatment was initiated. The log-rank test was used to compare time to death and time to LTF. The Cox proportional hazard model was used to determine predictors of mortality and LTF after DR-TB diagnosis. The Crude and adjusted Cox proportional hazard ratio was used to measure the strength of association whereas p-value less than 0.05 were used to declare statistically significant predictors.
RESULT
A total of 406 DR-TB patients were followed for 7084 person-months observations. Among the patients, 71 (17.5%) died and 32 (7.9%) were lost to follow up (LTF). The incidence density of death and LTF in the cohort was 9.8 and 4.5 per 1000 person-months, respectively. The median age of the study participants was 28 years (IQR: 27.1, 29.1). The overall cumulative survival probability of patients at the end of 24 months was 77.5% and 84.5% for the mortality and LTF, respectively. The independent predictors of death was chest radiographic findings (AHR = 0.37, 95% CI: 0.17-0.79) and HIV serostatus 2.98 (95% CI: 1.72-5.19). Drug adverse effect (AHR = 6.1; 95% CI: 2.5, 14.34) and culture test result (AHR = 0.1; 95% CI: 0.1, 0.3) were independent predictors of LTF.
CONCLUSION
This study concluded that drug-resistant tuberculosis mortality and LTF remains high in the study area. Continual support of the integration of TB/HIV service with emphasis and work to identified predictors may help in reducing drug-resistant tuberculosis mortality and LTF.
Identifiants
pubmed: 33956812
doi: 10.1371/journal.pone.0250804
pii: PONE-D-21-04578
pmc: PMC8101723
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250804Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Infect Dis. 2019 Sep 18;19(1):817
pubmed: 31533661
Epidemiol Infect. 2013 Jun;141(6):1223-31
pubmed: 22846385
Tuberculosis (Edinb). 2017 Mar;103:44-51
pubmed: 28237033
Int J Tuberc Lung Dis. 2013 Mar;17(3):299-307
pubmed: 23211716
Int J Infect Dis. 2020 Sep;98:420-439
pubmed: 32645375
BMC Infect Dis. 2017 Aug 4;17(1):543
pubmed: 28778187
Tuberc Res Treat. 2019 Feb 12;2019:3569018
pubmed: 30891315
J Trop Med. 2017;2017:9241238
pubmed: 28808447
BMC Public Health. 2019 Feb 7;19(1):165
pubmed: 30732601
BMC Infect Dis. 2018 Sep 27;18(1):486
pubmed: 30261852
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
Exp Ther Med. 2016 Mar;11(3):777-782
pubmed: 26997992
Public Health Action. 2014 Oct 21;4(Suppl 2):S41-6
pubmed: 26393097
PLoS One. 2015 Dec 15;10(12):e0144244
pubmed: 26669737
Tuberculosis (Edinb). 2015 Jun;95 Suppl 1:S212-6
pubmed: 25829287
Eur Respir J. 2019 Jul 11;54(1):
pubmed: 31073080
Int J Tuberc Lung Dis. 2010 Apr;14(4):413-9
pubmed: 20202298
Expert Rev Respir Med. 2016 Sep;10(9):991-1002
pubmed: 27276361
Thorax. 2016 Sep;71(9):854-61
pubmed: 27012887
Infect Drug Resist. 2020 Oct 20;13:3699-3705
pubmed: 33116690
BMC Infect Dis. 2017 Aug 16;17(1):573
pubmed: 28814276
Cad Saude Publica. 2018 May 10;34(5):e00048217
pubmed: 29768580
Arch Public Health. 2020 Jul 31;78:69
pubmed: 32760587
PLoS One. 2019 Nov 19;14(11):e0225165
pubmed: 31743358
Int J Tuberc Lung Dis. 2012 Jan;16(1):90-7
pubmed: 22236852
Emerg Infect Dis. 2016 Mar;22(3):491-502
pubmed: 26889786
PLoS One. 2015 Mar 19;10(3):e0119332
pubmed: 25790076
Braz J Infect Dis. 2018 Jul - Aug;22(4):305-310
pubmed: 30086258
Epidemiol Infect. 2020 Oct 15;148:e258
pubmed: 33054897